3ZLR

Crystal structure of Bcl-xL in complex with inhibitor (WEHI-539).


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.026 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.158 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structure-Guided Design of a Selective Bcl-Xl Inhibitor

Lessene, G.L.Czabotar, P.E.Sleebs, B.E.Zobel, K.Lowes, K.L.Adams, J.M.Baell, J.B.Colman, P.M.Deshayes, K.Fairbrother, W.J.Flygare, J.A.Gibbons, P.Kersten, W.J.A.Kulasegaram, S.Moss, R.M.Parisot, J.P.Smith, B.J.Street, I.P.Yang, H.Huang, D.C.S.Watson, K.G.

(2013) Nat.Chem.Biol. 9: 390

  • DOI: 10.1038/nchembio.1246
  • Primary Citation of Related Structures:  3ZK6, 3ZLN, 3ZLO

  • PubMed Abstract: 
  • The prosurvival BCL-2 family protein BCL-X(L) is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. Enhancing apoptotic responses by inhibiting BCL-X(L) will most likely have widespread utility ...

    The prosurvival BCL-2 family protein BCL-X(L) is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. Enhancing apoptotic responses by inhibiting BCL-X(L) will most likely have widespread utility in cancer treatment and, instead of inhibiting multiple prosurvival BCL-2 family members, a BCL-X(L)-selective inhibitor would be expected to minimize the toxicity to normal tissues. We describe the use of a high-throughput screen to discover a new series of small molecules targeting BCL-X(L) and their structure-guided development by medicinal chemistry. The optimized compound, WEHI-539 (7), has high affinity (subnanomolar) and selectivity for BCL-X(L) and potently kills cells by selectively antagonizing its prosurvival activity. WEHI-539 will be an invaluable tool for distinguishing the roles of BCL-X(L) from those of its prosurvival relatives, both in normal cells and notably in malignant tumor cells, many of which may prove to rely upon BCL-X(L) for their sustained growth.


    Organizational Affiliation

    Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. glessene@wehi.edu.au




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
BCL-2-LIKE PROTEIN 1
A, B
158Homo sapiensGene Names: BCL2L1 (BCL2L, BCLX)
Find proteins for Q07817 (Homo sapiens)
Go to Gene View: BCL2L1
Go to UniProtKB:  Q07817
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
X0B
Query on X0B

Download SDF File 
Download CCD File 
A, B
5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid
C31 H29 N5 O3 S2
JKMWZKPAXZBYEH-JWHWKPFMSA-N
 Ligand Interaction
SO4
Query on SO4

Download SDF File 
Download CCD File 
A, B
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
EDO
Query on EDO

Download SDF File 
Download CCD File 
A
1,2-ETHANEDIOL
ETHYLENE GLYCOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
X0BKd: 0.6 nM BINDINGMOAD
X0BKd: 0.55 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.026 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.158 
  • Space Group: P 43 2 2
Unit Cell:
Length (Å)Angle (°)
a = 56.241α = 90.00
b = 56.241β = 90.00
c = 211.950γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
PHASERphasing
PHENIXrefinement
XDSdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-04-24
    Type: Initial release
  • Version 1.1: 2013-05-08
    Type: Database references
  • Version 1.2: 2013-06-05
    Type: Database references